Mattress momentum to sustain; margins hold key to print
After a 78% PAT surge in FY26, the mattress segment's growth curve enters Q1. Watch margin resilience and whether consumer demand holds post-festival season lull.
The Setup
Sheela Foam enters Q1 FY27 on the back of a transformational FY26: consolidated PAT surged 78% YoY to ₹161 Cr, revenue grew 11%, and the mattress segment emerged as the growth spine—logging double-digit growth through the year. The composite merger with Kurlon Enterprise Limited (completed Apr 2026) added footprint but also integration drag; Q1 will be the first full quarter of blended operations. Price momentum is bullish (₹790.6, +73% off the 52-week low, above all key moving averages), but FII ownership has softened to 4.15% (from 6.2% a year ago). This print will test whether the mattress surge can sustain Q1's tougher seasonality and whether margins hold.
What to Expect
~₹350–380 Cr
In line with Q4 momentum (₹360 Cr run-rate) and mattress growth trajectory; absorbs summer season volatility
~₹35–42 Cr
Margin recovery in FY26 normalized to 10–11% range; watch for operating leverage and merger costs
Double-digit %
Segment has been the growth lever; expect steady momentum but Q1 faces post-holiday demand normalization
~16–17%
Recovery intact from COVID lows; watch commodity costs and input inflation
A strong print would show mattress volumes sustaining double-digit growth, EBITDA margin staying above 16%, and consolidated revenue tracking the ₹360–370 Cr zone (Q4 level or higher) despite Q1 seasonality. Merger-related expenses should show up clearly; if they compress below expectations, operating leverage improves the narrative. A weak print would flag mattress growth cooling to mid-single digits, margin compression below 15% (signaling input cost pressures or mix headwind), or revenue miss the ₹340 Cr floor due to demand softness post-festival season. Any guidance walk or commentary on FY27 full-year trajectory will carry weight given the strong FY26 base.
On Track?
Yes, but with caveats. FY26 saw ₹161 Cr PAT on ₹1,447 Cr revenue (11.1% net margin)—a recovery from prior-year challenges. The Q4 FY26 sprint (revenue +24% QoQ, PAT +78% YoY) was buoyed by pent-up mattress demand and margin normalization post-COVID pricing pressures. Q1 entering a calendar trough (summer, post-wedding season, school holidays = lower discretionary spend) and integrating a sizable acquisition (Kurlon) means management's forward guidance and tone on FY27 targets will matter as much as the headline numbers. If mattress growth persists and margins hold above 10%, the full-year trajectory remains intact.
Street View
Since Last Quarter
1 · Kurlon Merger Complete (Apr 2026)
4.88M new shares listed post-amalgamation; fractional share compensation (₹3.07L) paid in May. Integration ongoing; Q1 will show first blended quarter. Watch management guidance on synergies, cost rationalization, and overlap resolution.
2 · Board Reconstitution (May–Jun 2026)
Three independent directors (Som Mittal, Ravindra Dhariwal, Anil Tandon) completed second term (Jun 6); new IDs appointed including Neeraj Jain (CA, Company Secretary). Routine governance refresh; no material red flags.
3 · FY26 Final Dividend & Shareholder Distribution (Jun 2026)
Board approved ₹1/share (20% on ₹5 FV) for FY26; record date Jul 9, paid post-AGM (Jul 16). Signals confidence in cash generation; consistent with prior years.
4 · Updated Annual Report—Mattress Volume Highlight (Jul 13)
Sheela Foam updated FY26 Annual Report to explicitly call out mattress volume growth in the Corporate Overview. Signals management's emphasis on this segment as the growth narrative post-Kurlon. Watch for this momentum quantification in Q1.
5 · Trading Window Closure (Jun 30)
Routine pre-result window closure per SEBI Insider Trading Regulations. No insider activity signaled.
Three Things to Watch
1. Mattress segment metrics & growth rate: Management will likely detail segment revenues and volumes in the result commentary. A print showing mattress double-digit growth holds the bull thesis. Any deceleration below 8% invites questions about demand shift or competitive pressure. 2. Margin bridge & Kurlon synergies: Expect the board to discuss integration progress, overlapping costs (manufacturing, sales force, distribution), and what hit (or upside) Q1 took. A credible roadmap to ₹50 Cr+ annual synergies would reassure the market; vague commentary raises integration risk. 3. FY27 guidance & consumer durables outlook: Post-strong FY26, management's tone on full-year growth (revenue CAGR, margin sustainability) and macroeconomic headwinds (input inflation, credit tightness, rural consumption) will anchor the market's FY27 modeling.
Sheela Foam's Q1 print lands at an inflection: can mattress-led growth sustain past the summer trough and post-merger churn? The stock's +73% gain off the low and bullish price action suggest the market is already pricing a credible narrative. A beat on mattress volumes, steady margin hold, and clear Kurlon synergy roadmap will validate the bull case. A miss on any of these—or weakened FY27 guidance—risks a sharp repricing. The 3% dividend yield and value positioning offer downside support, but momentum traders will focus on execution. Watch the mattress segment grow-rate and management's confidence in FY27 full-year targets.
First ₹1,000 Cr Quarter; Volume Growth and Margins Both Miss
Sheela Foam hit a historic revenue milestone but the underlying growth was largely price-driven (14 percentage points of the 20% gain), while volume growth stalled at 6% versus management's 10%+ comfort level. EBITDA margins at 10.6% remain 440 basis points below the FY-2027 target, with further compression expected as inventory accounting gains unwind.
₹1,032 Cr
+25.6% YoY, beat 15%+ guidance
10.6%
+139 bps YoY; target 15% = 440 bps gap
6%
vs 10%+ management comfort level
14 pp of 20%
Remaining 6 pp from volume expansion
Sheela Foam delivered a structural milestone in Q1 FY-2027: the company's first ₹1,000+ crore quarterly revenue and first ₹100+ crore EBITDA quarter. The reported results — ₹1,032 Cr revenue (+25.6% YoY), ₹109 Cr EBITDA, and ₹62 Cr net profit — cleared the prior 15%+ guidance floor and speak to the scale the company has achieved in consolidated operations. But dig into the composition, and the story softens. Of the 20% standalone India revenue growth, roughly 14 percentage points came from price increases, leaving only 6% volume expansion. The company's own management flagged 10%+ volume growth as the comfort zone; 6% sits 40% below that threshold. Similarly, the FY-2027 EBITDA margin target of 15% is still 440 basis points away from the delivered 10.6%. These gaps — volume, margin, earnings quality — frame the real question: whether Sheela Foam is accelerating or masking softness with price.
Where the growth came from — and where it didn't
The revenue beat masks a composition problem. Standalone India revenue grew ₹138 Cr in absolute terms (from ₹623 Cr to ₹761 Cr), up 22% in value. Volume expanded just 6% — meaning the remaining 16 percentage points came from higher unit realization. Management attributes this to raw material cost pass-throughs: TDI and polyol — which together constitute 65-70% of mattress COGS — swung between +40% and -20% during Q1. The company raised prices to offset the volatility, pushing ASPs higher even as physical units shipped grew only modestly. This is defensible in the near term (customers accept price increases when input costs spike), but it raises a demand elasticity question: once volatility stabilizes and companies have less justification for price hikes, will 6% volume growth be the new normal? Management's confidence that 'double-digit volumes will return when volatility subsides' (expected Oct-Nov) hinges on that reversal. If it doesn't happen, the company faces a harder conversation about whether the market is simply slowing.
The margin gap: 440 basis points and counting
EBITDA margin expanded 139 basis points to 10.6% YoY (from 9.2% in Q1 FY-2026), a genuine operational gain. But the FY-2027 target is 15% — a 440-basis-point gap that management must close over the remaining three quarters. How? The call pinned the lever to 'gross margin improvement of 200 basis points' once raw material volatility subsides. That's plausible if prices stay firm and input costs normalize. But two headwinds loom. First: international margins are set to compress. Australia and Spain delivered exceptional EBITDA margins in Q1 — 12.8% and 14.7%, respectively — that management explicitly attributed to holding high-cost-basis inventory during a period of falling raw material prices. Management stated this margin benefit is 'not an ongoing sort of event' and guided to sustainable margins of 10-12% in those regions. That moderation will show up in Q2 results. Second: the company's own gross margin delta of 200 bps is not a given; it requires both price discipline (customers accept they keep the gains) and input normalization (costs don't spike again). Until Oct-Nov, the narrative is hedged.
Management's claims, fact-checked
Consolidated revenue >₹1,000 Cr, >₹100 Cr EBITDA in the first quarter
Delivered ₹1,032 Cr revenue, ₹109 Cr EBITDA
Supported
6% volume growth reflects price increases driving revenue, not demand weakness
14 pp of 20% revenue growth from price; 6% volume vs 10%+ internal target
Overstated
EBITDA margin improved 139 bps to 10.6% — margin expansion delivered
10.6% margin confirmed, but 440 bps below 15% FY-2027 target
Supported (near-term), unmet (full-year)
Australia and Spain margins (12.8%, 14.7%) reflect operational improvements
Management later admitted these were driven by low-cost inventory in transit; unsustainable as volatility normalizes
Overstated
Furlenco EBITDA growth 65% YoY to new levels of profitability
Q4 FY-2026 net profit ₹60 Cr included ₹27 Cr deferred tax asset; operating profit ~₹33 Cr; Q1 contribution lower
Contradicted (earnings quality issue)
What changed on this call
Three material clarifications emerged: 1. EBITDA margin target upgraded to 15% (from 11-12% bracket). The prior call guided for margins to 'improve from the 11-12% bracket.' This quarter management restated the target explicitly as 15% for FY-2027, a clear upgrade in aspiration but one that is 440 bps unmet and now explicit and measurable. 2. Volume growth guidance reset lower. The company no longer implies continuous double-digit volume growth. Instead, management now guides 'double-digit volumes by year-end,' signaling that H1 will likely remain in the single digits. The gap reflects a trade-off: price-driven FY27 growth to >15% (on track at +25.6% in Q1), but volume recovery is deferred. 3. International expectations moderated. Australia and Spain guidance reset to 10-12% EBITDA margins and 5% local-currency growth, down from the exceptional Q1 prints. This is a downgrade masked as prudence, but it's honest: management admits the Q1 inventory accounting benefit won't repeat.
The bull-bear ledger
BULL: Historic scale milestone achieved. First ₹1,000+ Cr revenue quarter in the company's history, driven by consolidated operations (India standalone ₹761 Cr, Australia ₹120 Cr, Spain ₹133 Cr, others). This is structural validation of the multi-geography, multi-brand strategy.
BULL: U2O segment (+81% YoY) validates unorganized-to-organized penetration. 10,000 dealers nationwide, pricing locked in at ~₹2,100/mattress (sustainable per management). This segment is the real growth engine and structurally undermonetized vs. Kurlon.
BULL: Kurlon synergies 75-80% realized, with ₹40 Cr upside in Q3. Integration 96-97% complete; operating units consolidated from 21 to 12. This is a working acquisition, not a bet.
BULL: FY-2027 guidance (>15% growth, 15% EBITDA margin, ₹1,000+ Cr international revenue) reaffirmed, not withdrawn. Management did not hedge or lower expectations; they doubled down on the FY-2027 targets despite Q1 margin shortfall.
BEAR: Volume growth at 6% vs 10%+ comfort zone = 40% miss on the key operational metric. This is the leading indicator of demand health. Until this recovers, confidence in upside is capped.
BEAR: EBITDA margin target 440 bps away, dependent on Oct-Nov volatility stabilization (no guarantee). The company's margin expansion lever is entirely macro-driven. Management cannot expand margins alone if raw material prices remain volatile.
BEAR: International margin compression coming. Australia/Spain Q1 margins (12.8%, 14.7%) inflated by inventory accounting. Moderation to 10-12% expected Q2. This will depress consolidated EBITDA margin next quarter.
BEAR: Earnings quality degraded by one-time items. Furlenco Q4 profit inflated by ₹27 Cr deferred tax asset; Australia/Spain margins driven by inventory accounting; these don't repeat.
BEAR: Price increases (14 pp of revenue growth) may not stick if macro softens. The 20% revenue growth is heavily dependent on price discipline. If demand weakens or competition increases, ASP gains could erode.
Risks, ranked by severity
Raw material volatility continues past Oct-Nov; stabilization fails to occur
HighThe entire FY-2027 margin target (15% EBITDA) and volume recovery narrative hinges on Oct-Nov stabilization. If Middle East tensions persist or new supply shocks hit, the company loses both its margin lever and its volume recovery catalyst. This is an external risk the company cannot control.
Volume growth remains in single digits through FY-2027; double-digit recovery doesn't materialize
High6% volume growth is 40% below management's comfort zone and signals either demand weakness or severe pricing headwinds. If this persists, the FY-2027 >15% growth target shifts entirely to pricing (unsustainable), and the company misses the earnings inflection it has been guiding for.
International (Australia/Spain) margin compression sharper than guided (10-12%); hits consolidated margin
MediumThe Q1 inventory accounting benefit was worth ~200-300 bps of margin in Australia and Spain. Unwinding this in Q2-Q3 will create a visible step-down in consolidated EBITDA margin that may disappoint if not properly communicated.
Furlenco profitability lumpy due to deferred tax and one-time items; associate contribution declines
MediumFurlenco is supposed to be the high-margin affiliate on an IPO trajectory, but Q4 showed ₹27 Cr of ₹60 Cr net profit was deferred tax (non-cash). Operating profit closer to ₹33 Cr. If this volatility persists, it clouds the IPO case and the earnings bridge for Sheela Foam's consolidated PAT.
Kurlon synergy realization delays; ₹40 Cr pending on Q3 capex execution
LowMachines have arrived and are under installation; management is confident. Risk is low, but if execution slips, it costs the company ₹40 Cr of EBITDA and pushes the margin target further out.
How the street is reading this
The market's initial verdict on the Q1 result was skeptical and that skepticism has held. The stock opened up +0.47% on the day of the announcement, but faded to -11.8% by day 3 and -11.56% by day 5. That fade — roughly 12 percentage points over five trading days — signals that investors initially reacted to the headline (₹1,032 Cr revenue beat), then dug into the margins, volumes, and earnings quality, and decided the story was less compelling on second read. The stock now trades at ₹699.95, -15.92% from its all-time high, and sits below its 20-day moving average (₹739.58) and 50-day moving average (₹735.35), though still above its 200-day moving average (₹614.37). Within its 52-week range of ₹456.8–₹832.45, the stock has recovered 53.23% off the low, but the sharp drawdown from ATH and the post-result fade suggest the market is repricing downside risk.
Ownership data confirm this mood. Foreign institutional investors (FII) hold 4.17% as of Q1 FY-2027, down marginally from 4.15% in Q4, a small trim. Domestic institutional investors (DII) have cut more sharply: from 20.56% in Q4 to 18.52% in Q1, a loss of 204 basis points. Promoter holding remains stable at 65.39% (up slightly from 65.69% prior quarter). The narrative is: foreign money is uncommitted, domestic institutions are trimming, promoters are steady. That composition — high promoter, low FII, falling DII — is typical of a stock in a repricing phase where growth expectations are being reset lower.
The debate: What this quarter really means
1 · Raw material stabilization (Oct-Nov expected window)
Management has pinned the entire margin and volume recovery narrative to TDI/polyol volatility subsiding by Oct-Nov 2026 (when Middle East tensions may ease). If prices stabilize, the company should be able to hold prices and see volume recover. If volatility persists (±40% swings continue), margin target moves out and volume recovery is delayed. This is the pivotal macro variable.
2 · Standalone India volume growth by Q3
The company needs to deliver standalone volume growth of at least 8-10% by Q3 FY-2027 to restore confidence in demand recovery. If Q2 also shows 6% or lower volume growth, the market will reprice the demand story as structurally softer, not temporarily constrained by volatility.
3 · Q2 international margin moderation (Australia/Spain)
Watch for Australia/Spain EBITDA margins in Q2 to normalize toward the 10-12% range management guided. This will show up as a 200-300 bps step-down in consolidated EBITDA margin and should be expected. If it happens, take it as confirmation that Q1's 12.8%/14.7% margins were inventory-driven and unsustainable.
4 · Q3 Kurlon synergy realization (₹40 Cr upside)
The company has ₹40 Cr of synergy benefit pending in Q3 when new machine installation is complete. If this materializes on time and adds to Q3 EBITDA, it will be a concrete proof point that the acquisition is working and will help the company approach the 15% EBITDA margin target.
Sheela Foam has hit a historic scale milestone in Q1 FY-2027 — the first ₹1,000+ crore quarterly revenue — but the operational performance underneath is softer. Revenue growth was 70% price-driven, 30% volume-driven; the company's own comfort zone is 60-40 or better. EBITDA margins are 440 basis points away from the FY-2027 target, and the path depends almost entirely on macro stabilization (raw material prices, which the company cannot control). International operations delivered exceptional margins in Q1, but those were inventory-accounting benefits that will unwind next quarter. This is not a 'red flag' quarter — the company beat headline guidance and delivered real revenue growth. But it's not the step-change inflection story that management has been pitching either. The company is executing, but execution is steadier than growth. Earnings quality is mixed (inventory gains, deferred tax inflation, price-driven growth). The street's skepticism — evident in the 12-point post-result fade and the 16% drawdown from ATH — is warranted. Until volume growth accelerates (target: ≥8% by Q3) and the company demonstrates that EBITDA margins can hold or expand as volatility recedes, the repricing lower is justified. The number to track: Standalone India volume growth in Q2 FY-2027. If it stays at 6% or falls further, the demand recovery narrative is broken. If it accelerates to 8%+ in Q2, confidence in double-digit volume growth by year-end begins to restore. That single metric will determine whether the FY-2027 guidance (>15% revenue, 15% EBITDA margin) is achievable or a walk-down waiting to happen.
Sheela Foam Q1FY27: consolidated PAT surges 9.5x YoY on weak base, revenue up 26%
PAT +851.6% YoY · revenue +25.63% · margins expanding · beat vs street
₹1,031.94 Cr
+25.63% YoY
₹62.34 Cr
+851.6% YoY
5.95%
+5.1pp YoY
₹5.63
Sheela Foam's consolidated PAT for Q1 FY27 came in at ₹62.3 Cr against ₹6.55 Cr a year ago — the ~9.5x jump management itself highlighted — on revenue of ₹1,031.9 Cr, up 25.6% YoY though down 1.7% QoQ from Q4 FY26's ₹1,050.1 Cr. YoY is the right lens here: Q1 FY26 was an unusually weak quarter (NPM just 0.86%), so even after stripping the ₹6.26 Cr exceptional gain on the Haridwar land sale, adjusted PAT of ~₹56 Cr is still up roughly 756% YoY — real recovery, not just base-effect optics, but the raw 9.5x headline overstates the underlying run-rate. Standalone PAT, by contrast, grew a much smaller ~3.1x YoY (₹43.9 Cr vs ₹10.7 Cr) — the gap versus consolidated is driven by a 42% YoY jump in overseas subsidiary revenue (₹262.7 Cr vs ₹184.9 Cr) and an 81% YoY rise in the Furlenco/House of Kieraya JV profit share (₹3.11 Cr vs ₹1.72 Cr), both of which sit only in the consolidated books.
Q1 FY-2027 vs prior quarters
Margins tell a more mixed story than the PAT headline suggests. Consolidated NPM improved sharply YoY (6.0% vs 0.86%) but slipped QoQ from 8.7%, while EBITDA-level margin (PBT before exceptionals + finance cost + depreciation, over revenue) was ~12.1% this quarter versus ~12.6% in Q4 FY26 and ~9.2% a year ago — expanding YoY but giving back some of the sequential gain. That keeps margins within the '11-12% bracket' management flagged as the current level on the Q4 FY26 call, rather than showing the clear step-up toward improvement it had guided for; the 6.26 Cr one-off gain also flatters the reported bottom line versus the underlying margin trend.
The stock went into the print at ₹768.05, up 2.1% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
Management guides for value growth exceeding 15% in FY'27, driven by higher selling prices and continued volume momentum from its Kurlon, U2O, and e-commerce initiatives. They expect core EBITDA margins to improve from the current 11-12% bracket, supported by successful price pass-throughs and operational efficiencies.
— This quarter: beat
On guidance and Street: management's FY27 call was for value growth exceeding 15%, and Q1's 25.6% YoY revenue growth already clears that bar. Pre-result brokerage estimates (Univest) had pegged Q1 revenue at ₹907-1,044 Cr and PAT at just ₹6-8 Cr — actual revenue landed near the top of that range, but PAT beat the estimate by roughly 8x, a sharp street beat on profitability even allowing for the low comparison base and the one-off gain. Management's own release framed the quarter as a continuation of 'healthy momentum' in mattress and foam, with e-commerce and U2O initiatives 'gaining scale' — the 25.6% topline growth and Kurlon-driven consolidated strength support that framing, though the flat-to-lower QoQ margin undercuts any claim of margin momentum this specific quarter.
W1
Whether EBITDA margin breaks out of the 11-12% bracket toward management's guided improvement in coming quarters
W2
PAT run-rate once the ₹6.26 Cr exceptional gain rolls off — adjusted PAT this quarter was ~₹56 Cr
W3
Furlenco/House of Kieraya JV profit contribution trajectory (+81% YoY to ₹3.11 Cr) at the current 34.53% equity stake
Both include a ₹6.26 Cr exceptional gain (Haridwar land/building sale, held for sale); consolidated PAT = ₹59.23 Cr (post-tax, pre-JV) + ₹3.11 Cr JV share (House of Kieraya/Furlenco) = ₹62.34 Cr, of which ₹61.44 Cr attributable to shareholders and ₹0.90 Cr to NCI; year-ago (Jun'25) consolidated total PAT reconciles to ₹6.55 Cr (VII+VIII / shareholders+NCI cross-check), matching management's own '9.5x' framing — our DB record of ₹7.16 Cr for that quarter appears stale/pre-restatement.
Record size; volume growth lags, margins hedged on volatility
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Beat revenue/PAT absolute numbers; reaffirmed but did not upgrade guidance. Volume growth gap (6% vs 10%+ desired) and Furlenco earnings quality (₹27 Cr of ₹60 Cr Q4 net profit from deferred tax) warrant caution.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Sheela Foam delivered a strong milestone quarter (first ₹1,000 Cr revenue, ₹100 Cr+ EBITDA, +26% consolidated growth) and beat prior 15%+ guidance. However, delivered volume growth of only 6% lags management's 10%+ comfort level, and the 15% EBITDA margin target for FY27 remains unmet at 10.6%, dependent on raw material volatility subsiding by Oct-Nov. International operations (Australia +31%, Spain +54%) benefited from inventory accounting effects management admits are temporary. The call tone is confident but heavily hedged; near-term earnings quality is acceptable but not exceptional.
₹1032 Cr
Revenue · +25.6% YoY₹62 Cr
Reported PAT · +770.7% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Consolidated revenue >₹1,000 Cr, >₹100 Cr EBITDA in first quarter
METDelivered ₹1,032 Cr revenue, ₹109 Cr EBITDA, both confirmed in results
Volume growth 6% standalone India reflects price increases, not demand weakness
OVERSTATEDRevenue +20%, volume +6% = 14% price gap; management frames as temporary lag pending volatility stabilization
EBITDA margin improved 139 bps to 10.6% from 9.2%; margin expansion delivered
MET10.6% margin confirmed; delivered OPM 11.2% also shows expansion, but below stated 15% target
Australia/Spain exceptional margins (12.8%, 14.7%) reflect operational improvements
OVERSTATEDManagement later admitted inventory carrying lower-cost raw materials drove benefit; unsustainable once volatility stabilizes
Furlenco EBITDA grew 65% YoY to new levels of profitability
MISSLast year Q4 net profit ₹60 Cr, but ₹27 Cr was deferred tax asset; operating profit ~₹9 Cr/qtr; quality issue
Earnings quality
What changed since the last call
EBITDA margin target clarified to 15%
UpgradePrior call guided 'improve from 11-12% bracket'; now explicitly 'target 15% EBITDA margin for next year' (FY27). Delivered Q1 at 10.6%, so guidance is 430 bps higher but unmet. This is a clearer restatement, likely upgrade in aspiration.
Volume growth guidance reset lower
DowngradeStandalone volume growth Q1 came at 6%; management now says 'double-digit by year-end' (vs prior implied continuous double-digit). Gap reflects price-driven revenue growth masking volume softness; risk if demand doesn't recover.
International subsidiary expectations moderated
DowngradeAustralia/Spain Q1 margins (12.8%, 14.7%) acknowledged as temporary inventory benefits. Guidance reset to sustainable 10-12% EBITDA margins, 5% growth in local currency (EUR, AUD). Prior call implied stronger overseas momentum.
The Q&A
Analysts pressed hard on volume growth weakness (6% vs double-digit history), margin sustainability given raw material volatility, and Furlenco profitability (Q-o-Q decline). Management held but hedged repeatedly: volume recovery 'when volatility subsides,' margins 'on the same track' if gross margins stabilize 2%, Furlenco 'not a degrowth' due to deferred tax accounting. Confidence is strong on absolute size but cautious on guidance execution; not a defensive call, but not fully reassuring.
Inventory policy, margin sustainability — Ritesh Shah, Investec
AnsweredIndia holds 15-30 days; Australia/Spain held larger inventory during volatile period. Not sustainable going forward. Margins will moderate as prices normalize.
U2O pricing, volume-value gap — Ritesh Shah, Investec
AnsweredInitial launch at low price to build volume; faced channel margin pressure; raised prices; now settled and sustainable at current levels. Channel accepted.
Standalone volume growth, desired level — Ritesh Shah, Investec
PartialShould target sub-10%; currently 6%, not happy. But better than industry; once volatility subsides, expect double-digit.
Furlenco Q-o-Q profit decline — Pritesh Chheda, Lucky Investment Managers
AnsweredQ4 last year had ₹60 Cr net profit, but ₹27 Cr was deferred tax asset (one-time, end-of-year recognition). Operating profit ₹33 Cr. Q1 had lower contribution due to expenses; but operating profit expected higher full year.
India business volume vs demand — Pritesh Chheda, Lucky Investment Managers
PartialValue growth also accelerated (+15%, +26%). Price hike of quantum seen creates balance; if price hike 10-15%, volume would be double-digit. Confident as volatility subsides, volumes recover.
Return on capital, balance sheet trajectory — Pankaj Tibrewal, IKIGAI Asset Managers
AnsweredVolatility expected until Oct-Nov. Expect better profitability by year-end. ROCE currently ~10%, target 20-25% in 3 years. Free cash flow ₹150-200 Cr/year; debt (India ₹300+ Cr, overseas ₹350 Cr) will clear in 1 year (India) and 5 years (overseas).
International operations sustainability — Dikshi Jain, InCred Research
AnsweredThis quarter exceptional. Combined EBITDA margin 13-13.5%. Should normalize to 10-12%, 5% growth in local currency. Spain done EUR 12M in Q1 (vs EUR 9-10M regular); might sustain higher due to product improvements, but conservative guidance is 10-12%.
COCO store capex and expansion — Dikshi Jain, InCred Research
Answered₹27 lakh per store capex + ₹20-22 lakh working capital (COCO). 50 stores target; 2,000 sq ft, urban key areas. ₹25 Cr for 50-store plan.
Cost inflation, raw material pricing — Garvit Goyal, Serene Alpha
AnsweredPrices very volatile (±40% to -20%). Doing commensurate price increases to customers. Lag risk if volatility very high and moves fast (inventory in transit); impact seen in Q1. Majority covered.
Margin guidance consistency — Rachna Kukreja, SiMPL
PartialGuided 11-12%, not 13%. Do stand by it. But volatility makes it hard to comment. Pretty confident on same track. Gross margins down more than target; even 2% improvement gets us to target.
Furlenco vs RentoMojo competitive positioning — Navin, iThought PMS
AnsweredSame business area; RentoMojo more mass, Furlenco more premium. RentoMojo higher utility mix; Furlenco higher furniture. Premium to RentoMojo.
Kurlon integration status and synergies — Arjun Agarwal, Individual Investor
AnsweredIntegration 96-97% complete (backend, frontend, HR, IT). Operating units reduced 21 to 12. Synergies: 75-80% realized, 15-20% on the way. Market share in organized mattress ~20% combined.
Guidance
FY27 >15% growth (clocked 20% Q1, confident of >15% for full year)
HighManagement states Q1 at 20%, targeting 15% as guidance floor. Sees double-digit volume growth returning post-volatility stabilization (Oct-Nov).
International operations to cross ₹1,000 Cr revenue FY27 (₹800-850 Cr FY26)
HighAustralia/Spain combined Q1 trending strong; Australia +31%, Spain +54% guides path to ₹1,000+ Cr
EBITDA margin target 15% FY27 (from prior 11-12% bracket)
MediumQ1 delivered 10.6% margin; management reaffirms 15% target but hedges on volatility. Gross margins need +2% improvement to reach 15%; lever is raw material normalization.
₹25 Cr capex for 50-store COCO store rollout (₹27L per store + WC)
HighOn track; 42 stores operational, targeting 100 stores. Per-store unit economics proven (~₹27L capex + ₹20-22L WC).
Risks the call surfaced
Raw material cost volatility
HighTDI/polyol prices swung ±40% to -20% in Q1; management estimates 65-70% of COGS. Lag risk if volatility moves fast (inventory in transit). Management passed through prices but hedges on continued pressure.
Volume growth momentum loss
HighStandalone volume growth 6% vs historical double-digit and management's desired 10%+ comfort zone. 14% price increase needed to drive 20% revenue growth; demand elasticity risk if prices don't stick or macro softens.
International margin unsustainability
MediumAustralia/Spain Q1 margins (12.8%, 14.7%) benefited from carrying high-cost inventory at time of falling raw material prices. Management explicitly states margins will compress to 10-12% sustainable levels once inventory normalizes in Q2.
Furlenco earnings quality
MediumQ4 FY26 net profit ₹60 Cr, but ₹27 Cr was deferred tax asset recognition (one-time, end-of-year). Operating profit closer to ₹33 Cr. Q1 showed lower contribution; profitability lumpy and inflated by tax benefits.
Kurlon synergy realization lag
Low75-80% of synergies realized; ₹40 Cr remaining pending new machine installation in Q3. Execution risk if capex delays or ramp-up underperforms.
Management
Score 6/10. Transparent on headwinds (raw material volatility, volume gap, inventory benefits) but defensive on targets. Candid on deferred tax accounting in Furlenco; hedges repeatedly on volatility recovery timing. Not evasive, but cautious tone. Beat absolute revenue (25.6% vs 15% guidance) and PAT targets; EBITDA margin at 10.6% vs 11-12% prior guidance. Synergies 75-80% realized vs 100%. Volume growth 6% vs internal 10%+ desired. Mixed track record; hits revenue targets but misses margin/operational efficiency targets.
1 · Oct-Nov 2026
Raw material price volatility expected to stabilize (Middle East conflict resolution window)
2 · Q3 FY27
₹40 Cr remaining Kurlon synergy realization from new machine installation
3 · Q2 FY27
Inventory levels normalize; overseas margin compression visible as lower-cost inventory runs off
The call tone is confident but heavily hedged; near-term earnings quality is acceptable but not exceptional.